Updated
NovartisNVS · Healthcare
$162.55+0.38%
Market cap$310.2B
IndustryDrug Manufacturers - General
Novartis (NVS) Revenue breakdown
By segment, Innovative Medicines is the largest at 82% of fiscal 2022 revenue, growing 4% a year over 6 years.
Summary
By region, US is the largest at 43% of fiscal 2025 revenue, growing 12% a year over 4 years.
Revenue by segment
Fiscal years, as Novartis reports them in its 10-K filings; fiscal 2022 total $51.6B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicines | $32.5B | $32.9B | $35.6B | $38.5B | $39.8B | $42.8B | $42.1B | 82% |
| Sandoz | $10.2B | $10.2B | $10.0B | $9.9B | $9.8B | $9.8B | $9.5B | 18% |
| Alcon | $6.5B | — | — | — | — | — | — | — |
| Corporate | -$728M | -$743M | -$836M | -$871M | -$981M | -$975M | -$1.0B | -2% |
Revenue by region
Fiscal years, as Novartis reports them in its 10-K filings; fiscal 2025 total $54.5B.
| Regions | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| US | $14.9B | $15.9B | $18.0B | $21.1B | $23.3B | 43% |
| Other | $16.3B | $17.4B | $19.5B | $20.3B | $21.7B | 40% |
| China | $2.8B | $2.9B | $3.3B | $3.9B | $4.2B | 8% |
| Germany | $3.6B | $3.1B | $3.4B | $3.7B | $3.9B | 7% |
| Switzerland | $926M | $1.0B | $1.3B | $1.3B | $1.4B | 3% |
| Japan | $2.3B | — | — | — | — | — |
| France | $2.0B | $1.8B | — | — | — | — |
Questions about Novartis
Where does Novartis make its money?
In fiscal 2022, by segment: Innovative Medicines $42.1B, Sandoz $9.5B, Corporate -$1.0B.
From Novartis's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.